Cargando…

Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of...

Descripción completa

Detalles Bibliográficos
Autores principales: Kerr, Caroline P., Grudzinski, Joseph J., Nguyen, Thanh Phuong, Hernandez, Reinier, Weichert, Jamey P., Morris, Zachary S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865370/
https://www.ncbi.nlm.nih.gov/pubmed/36678756
http://dx.doi.org/10.3390/pharmaceutics15010128
_version_ 1784875820679954432
author Kerr, Caroline P.
Grudzinski, Joseph J.
Nguyen, Thanh Phuong
Hernandez, Reinier
Weichert, Jamey P.
Morris, Zachary S.
author_facet Kerr, Caroline P.
Grudzinski, Joseph J.
Nguyen, Thanh Phuong
Hernandez, Reinier
Weichert, Jamey P.
Morris, Zachary S.
author_sort Kerr, Caroline P.
collection PubMed
description Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention—a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in preclinical studies, whereas results of clinical studies have been mixed. Several clinical trials combining TRT and immune checkpoint blockade have been initiated based on preclinical studies combining these with EBRT and/or TRT. Despite the interest in translation of TRT and immunotherapy combinations, many questions remain surrounding the mechanisms of interaction and the optimal approach to clinical implementation of these combinations. This review highlights the mechanisms of interaction between anti-tumor immunity and radiation therapy and the status of basic and translational research and clinical trials investigating combinations of TRT and immunotherapies.
format Online
Article
Text
id pubmed-9865370
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98653702023-01-22 Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment Kerr, Caroline P. Grudzinski, Joseph J. Nguyen, Thanh Phuong Hernandez, Reinier Weichert, Jamey P. Morris, Zachary S. Pharmaceutics Review Targeted radionuclide therapy (TRT) and immunotherapy are rapidly growing classes of cancer treatments. Basic, translational, and clinical research are now investigating therapeutic combinations of these agents. In comparison to external beam radiation therapy (EBRT), TRT has the unique advantage of treating all disease sites following intravenous injection and selective tumor uptake and retention—a particularly beneficial property in metastatic disease settings. The therapeutic value of combining radiation therapy with immune checkpoint blockade to treat metastases has been demonstrated in preclinical studies, whereas results of clinical studies have been mixed. Several clinical trials combining TRT and immune checkpoint blockade have been initiated based on preclinical studies combining these with EBRT and/or TRT. Despite the interest in translation of TRT and immunotherapy combinations, many questions remain surrounding the mechanisms of interaction and the optimal approach to clinical implementation of these combinations. This review highlights the mechanisms of interaction between anti-tumor immunity and radiation therapy and the status of basic and translational research and clinical trials investigating combinations of TRT and immunotherapies. MDPI 2022-12-30 /pmc/articles/PMC9865370/ /pubmed/36678756 http://dx.doi.org/10.3390/pharmaceutics15010128 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kerr, Caroline P.
Grudzinski, Joseph J.
Nguyen, Thanh Phuong
Hernandez, Reinier
Weichert, Jamey P.
Morris, Zachary S.
Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
title Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
title_full Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
title_fullStr Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
title_full_unstemmed Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
title_short Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
title_sort developments in combining targeted radionuclide therapies and immunotherapies for cancer treatment
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865370/
https://www.ncbi.nlm.nih.gov/pubmed/36678756
http://dx.doi.org/10.3390/pharmaceutics15010128
work_keys_str_mv AT kerrcarolinep developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment
AT grudzinskijosephj developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment
AT nguyenthanhphuong developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment
AT hernandezreinier developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment
AT weichertjameyp developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment
AT morriszacharys developmentsincombiningtargetedradionuclidetherapiesandimmunotherapiesforcancertreatment